• H2 growth drivers: Revenue growth in the second half will be propelled by new product launches, including aflibercept (Eylea) and Kirsty (insulin aspart), alongside continued market traction from established biosimilars.
• Syngene turnaround strategy: After facing setbacks from over-dependence on a single CDMO client and commoditized offerings, Syngene is diversifying its customer base and utilizing its US Bayview biologics facility to drive a turnaround by the end of the fiscal year.
• Corporate deleveraging plans: Biocon achieved a 22% reduction in interest costs during the quarter and plans to continuously pay down corporate debt using generated free cash flow.
• US tariff impact: Management views proposed US tariffs on generic drugs as counterintuitive and unlikely to be enacted, as generics and biosimilars generate critical cost savings for the US healthcare system.
• Executive succession roadmap: The leadership transition to Claire Mazumdar is part of a five-year succession plan designed for long-term continuity rather than an immediate handover.